The PreciseOnco research consortium has been awarded €14.9 million in funding from the European Union’s Innovative ...
The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to ...
Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.
Surgery remains one of the most effective treatments for localized cancer. The primary aim is complete tumor removal with ...